Clinical Trial Update: Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases [Phase 1, Phase 2]

View source ↗

Summary

Results have been posted for a completed Phase 1/2 study of carboplatin and temozolomide in patients with recurrent and symptomatic residual brain metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Brain Tumor

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Temodar (Temozolomide)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Brain Tumor, Brain Metastases | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-05-06